Fatima Cardoso, MD, on Breast Cancer: MammaPrint as Guidance for Adjuvant Chemotherapy
ASCO20 Virtual Scientific Program
Fatima Cardoso, MD, of Lisbon’s Champalimaud Cancer Center, discusses the long-term results of MINDACT, a large prospective trial showing the clinical utility of the 70-gene signature MammaPrint for adjuvant chemotherapy decision-making. The primary distant metastasis–free survival endpoint at 5 years continued to be met in chemotherapy-untreated women with clinical-high/genomic-low risk disease (Abstract 506).
The ASCO Post Staff
Eric Zhou, PhD, of Dana-Farber Cancer Institute, discusses an existing online program called SHUTi (Sleep Healthy Using the Internet), that he and his team adapted to the needs of adolescent and young adult cancer survivors. After six online cognitive behavior therapy sessions delivered over 8 weeks, the 22 patients in the study reported a significant reduction in insomnia severity, daytime sleepiness, and fatigue as well as an overall improvement in quality of life.
The ASCO Post Staff
Patricia Pautier, MD, of Institut Gustave Roussy, discusses final results of the phase II LMS-02 study, which showed the combination of doxorubicin and trabectedin to be an effective first-line therapy for patients with leiomyosarcoma, with an acceptable safety profile (Abstract 11506).
The ASCO Post Staff
Merry-Jennifer Markham, MD, ASCO’s Cancer Communications Chair, gives her views on key papers presented at the ASCO20 Virtual Scientific Program, addressing gynecologic malignancies and COVID-19.
The ASCO Post Staff
Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses early data on ARV-110, an androgen receptor proteolysis–targeting chimera degrader, demonstrating antitumor activity in metastatic castration-resistant prostate cancer after treatment with enzalutamide and abiraterone (Abstract 3500).
The ASCO Post Staff
David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how circulating tumor DNA dynamics associate with treatment response and radiologic progression-free survival (Abstracts 5506, 5507, and 5508).
